In the case of ApcMin/+ mice, treatment with a PKA antagonist, Rp-8-Br-cAMPS, reduces tumor promotion and β-catenin levels, nuclear translocation, and expression of some of its target genes, such as c-Myc and cyclooxygenase-2 (Cox-2) [31]. Here, MYC is linked to neoplasm.